stockrowBiohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
Follow BHVN
Alert me
Biohaven Ltd. (BHVN) EV/Sales
As of 5 November 2026, Biohaven Ltd. (BHVN) trades at a EV/Sales of 2.2×. Over the past ten years it has ranged from 0.0× (December 2020) to 59.5× (June 2021); the current reading is higher than 67% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | 10.1× | (80.77%) |
| FY2020 | 52.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2022 | 6.1× | 10.60% |
| Mar 2022 | 5.5× | (45.89%) |
| Dec 2021 | 10.1× | (44.94%) |
| Sep 2021 | 18.4× | (44.85%) |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −1.3× |
| VERA Vera Therapeutics, Inc. compare | n/m |
| BHVN Biohaven Ltd. | 2.2× |
| AUPH Aurinia Pharmaceuticals Inc compare | 5.3× |
| ADMA ADMA Biologics Inc compare | 5.8× |
| VCEL Vericel Corporation compare | 7.6× |
| PVLA Palvella Therapeutics, Inc. compare | 48.1× |
| IMNM Immunome, Inc. compare | 121× |
| CLDX Celldex Therapeutics, Inc. compare | 1,691× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)